Literature DB >> 23079752

Adverse ophthalmic reaction in poppers users: case series of 'poppers maculopathy'.

A J Davies1, S P Kelly, S G Naylor, P R Bhatt, J P Mathews, J Sahni, R Haslett, M McKibbin.   

Abstract

BACKGROUND: Poppers are a recreational substance of abuse belonging to the alkyl nitrite family of compounds. In the United Kingdom, where they are legal to purchase but illegal to sell for human consumption, 10% of the general population have tried them. They are considered low risk to physical and mental health. Two recent case series from France demonstrated foveal pathology in individuals associated with poppers use.
METHOD: A case series of seven patients presenting to four hospitals in the United Kingdom with visual impairment and maculopathy associated with inhalation of poppers.
RESULTS: All patients experienced visual symptoms associated with poppers use. The majority had impaired visual acuity, central scotomata, distortion, or phosphenes. Clinical signs on fundoscopy ranged from normal foveal appearance to yellow, dome-shaped lesions at the foveola. Spectral domain optical coherence tomography (SD-OCT) showed varying degrees of disruption of the presumed inner segment/outer segment (IS/OS) junction. DISCUSSION: Although poppers have been in use for several decades, in 2007, following legislative changes, there was a change in the most commonly used compound from isobutyl nitrite to isopropyl nitrite. There were no reports of 'poppers maculopathy' before this. Poppers maculopathy may be missed if patients are not directly questioned about their use. The disruption or loss of the presumed IS/OS junction on SD-OCT are a characteristic feature. Further study of maculopathy in poppers users is now needed. Raising public awareness of the ocular risks associated with their use may be necessary.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079752      PMCID: PMC3496104          DOI: 10.1038/eye.2012.191

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  15 in total

1.  Irreversible blindness after amyl nitrite inhalation.

Authors:  H C Fledelius
Journal:  Acta Ophthalmol Scand       Date:  1999-12

2.  THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?

Authors:  A B HILL
Journal:  Proc R Soc Med       Date:  1965-05

3.  'Poppers maculopathy'--an emerging ophthalmic reaction to recreational substance abuse.

Authors:  A J Davies; S P Kelly; P R Bhatt
Journal:  Eye (Lond)       Date:  2012-03-09       Impact factor: 3.775

Review 4.  What is a cause and how do we know one? A grammar for pragmatic epidemiology.

Authors:  M Susser
Journal:  Am J Epidemiol       Date:  1991-04-01       Impact factor: 4.897

5.  High-resolution optical coherence tomography findings in solar maculopathy and the differential diagnosis of outer retinal holes.

Authors:  Jason Comander; Matthew Gardiner; John Loewenstein
Journal:  Am J Ophthalmol       Date:  2011-06-25       Impact factor: 5.258

Review 6.  Harmonisation in pharmacovigilance.

Authors:  I R Edwards; C Biriell
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

7.  Pharmacokinetics of a model organic nitrite inhalant and its alcohol metabolite in rats.

Authors:  W Kielbasa; H L Fung
Journal:  Drug Metab Dispos       Date:  2000-04       Impact factor: 3.922

8.  Nitrite inhalation in rats elevates tissue NOS III expression and alters tyrosine nitration and phosphorylation.

Authors:  W Kielbasa; H L Fung
Journal:  Biochem Biophys Res Commun       Date:  2000-08-28       Impact factor: 3.575

Review 9.  Nitric oxide: a review of its role in retinal function and disease.

Authors:  I M Goldstein; P Ostwald; S Roth
Journal:  Vision Res       Date:  1996-09       Impact factor: 1.886

10.  Popping and snorting volatile nitrites: a current fad for getting high.

Authors:  L T Sigell; F T Kapp; G A Fusaro; E D Nelson; R S Falck
Journal:  Am J Psychiatry       Date:  1978-10       Impact factor: 18.112

View more
  11 in total

1.  [Bilateral central scotoma in a 28-year-old patient with CADASIL syndrome].

Authors:  K A Wolf; M A Varde; B Wiechens
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

2.  Is the mechanism of 'poppers maculopathy' photic injury?

Authors:  M A P Fajgenbaum
Journal:  Eye (Lond)       Date:  2013-10-11       Impact factor: 3.775

3.  Response to Fajgenbaum.

Authors:  A J Davies; S P Kelly; S G Naylor; P R Bhatt; J P Mathews; J Sahni; R Haslett; M McKibbin
Journal:  Eye (Lond)       Date:  2013-10-11       Impact factor: 3.775

4.  Laser-Induced Photic Injury Phenocopies Macular Dystrophy.

Authors:  Lijuan Zhang; Andrew Zheng; Hongping Nie; Kavita V Bhavsar; Yu Xu; David H Sliney; Stephen L Trokel; Stephen H Tsang
Journal:  Ophthalmic Genet       Date:  2016       Impact factor: 1.803

5.  A case of maculopathy from rush poppers.

Authors:  Si-Tong Guo; Li-Bin Jiang
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

6.  Poppers retinopathy.

Authors:  Joshua Luis; Meena Virdi; Shahriar Nabili
Journal:  BMJ Case Rep       Date:  2016-03-07

Review 7.  Ocular manifestations of drug and alcohol abuse.

Authors:  Jason Peragallo; Valérie Biousse; Nancy J Newman
Journal:  Curr Opin Ophthalmol       Date:  2013-11       Impact factor: 3.761

8.  The prevalence of visual symptoms in poppers users: a global survey.

Authors:  Andrew J Davies; Rohan Borschmann; Simon P Kelly; John Ramsey; Jason Ferris; Adam R Winstock
Journal:  BMJ Open Ophthalmol       Date:  2017-04-03

9.  AOSLO imaging in poppers maculopathy shows high resolution loss of central macular cones.

Authors:  Cole N Rojas; Amani A Fawzi; Manjot K Gill
Journal:  Am J Ophthalmol Case Rep       Date:  2021-07-22

Review 10.  The role of multimodal imaging and vision function testing in ABCA4-related retinopathies and their relevance to future therapeutic interventions.

Authors:  Saoud Al-Khuzaei; Mital Shah; Charlotte R Foster; Jing Yu; Suzanne Broadgate; Stephanie Halford; Susan M Downes
Journal:  Ther Adv Ophthalmol       Date:  2021-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.